Dassault Systemes to join Medidata Solutions, accelerate life science industry innovation, to create patient-oriented experience with end-to-Sites

Dassault Systemes and Medidata Solutions, Inc. announced the signing of a definitive agreement , Dassault Systemes will be in accordance to $ 92.25 per share, the total market capitalization for $ 5.8 billion in cash transaction to acquire Medidata. Medidata Solutions is a leader in the digital transformation of the life sciences industry, committed to the clinical development, business intelligence and real-world data optimization. The acquisition has been unanimously by the boards of both companies. As of December 31, 2018, Medidata fiscal year on revenue of $ 636 million. After the acquisition of US-based Medidata clinical and business solutions, Dassault Systemes will experience by providing integrated business platform for the life sciences industry, with end to end support for business development, clinical trials, manufacturing, and new therapies and health science and technology technology, further strengthening its position as a technology enterprise. Bernard Charlès Vice Chairman of the Board and CEO of Dassault Systemes said: “Today this acquisition will be an important milestone in the life sciences industry, but also demonstrates the tremendous value of the virtual world in the development of complex personalized medicine and patient-oriented experience. technological innovation and industrial development requires multi-disciplinary platform of the method, the personnel, ideas and data connected the dots .Medidata is a leader in the field of clinical trials, to provide a good life on 3DEXPERIENCE scientific collaboration platform solutions supplement. recently, Medidata extends to reality circumstantial evidence and analysis of field CONTROL ENGINEERING China Copyright through powerful modeling and simulation technology, which fully shows that the virtual world will promote the development of a new generation of patients to participate in therapy. currently, we are in the life sciences industry to promote the transformation of an advantageous position, which fully demonstrates Dassault Systemes’ mission in promoting products, natural and harmonious development of life. “Medidata clinical expertise and cloud solutions to support global 1300 customers to develop smarter and implement treatment programs of Now commercialized, these customers include pharmaceutical and biotechnology companies, contract research organizations (CRO) as well as medical centers and sites and so on. Its solutions can improve decision making and accelerate the implementation process, strengthen supervision, minimize operationalRisk, reduce costs and adjust clinical trial program, greatly improve the efficiency and quality of clinical development projects. 2018 top 15 drugs in global sales of 13 species using the Medidata technology. 25 of the top 18 pharmaceutical companies and CRO clients in the top ten of all nine of Medidata. Medidata established in 1999, is headquartered in New York, with 16 offices in seven countries, including the United States, Japan, South Korea and the UK, a total of 2,800 employees. Tarek Sherif of Medidata chairman, co-founder and CEO, said: “Our mission is the most appropriate time to provide patients with the most accurate medical needs, advance the mission of our 20 years of innovation process, we engaged in the pillar where the life sciences industry. we have the same vision, values ​​and passion and Dassault Systemes, the two sides joined forces to promote the development of the life sciences industry through end to end business platform. “Medidata’s co-founder and president Glen de Vries said: “to promote new therapeutic innovation to create next-generation standard of care that we would set a start at the beginning of our commitment will eventually bring a lot of opportunities for our customers and patients, promote the development of life sciences in precision medical era.” Dassault system in 2012 began working products, natural and harmonious development of life, then has been steadily advancing relevant knowledge and expertise, promote the transformation of products in the field CONTROL ENGINEERING China Copyright , and collaborative, cross subject areas of biotechnology innovation and development. Dassault Systemes and the world’s top 20 biopharmaceutical companies, hundreds of biotechnology companies, medical device manufacturers, research institutions and government regulators cooperation Control Engineering Copyright , to develop and launch innovative medical products and technology to achieve full use of virtual patients experience the transformation of the world’s technology. Acquisition is expected to be completed in the last quarter of 2019. CONTROL ENGINEERING China Copyright , still need to obtain regulatory approval and the consent of the majority of shareholders Medidata, while also meeting other customary closing conditions.

Related articles